Highlights of This Issue 391

SPECIAL FEATURES

CCR Translations

393  Response to Combined Molecular Targeting: Defining the Role of P-STAT3
  Ann Marie Egloff and Jennifer R. Grandis
  See article p. 483

CCR New Strategies

396  New Strategies in Acute Lymphoblastic Leukemia: Translating Advances in Genomics into Clinical Practice
  Charles G. Mullighan

Molecular Pathways

401  Tumor Suppressor CHK2: Regulator of DNA Damage Response and Mediator of Chromosomal Stability
  Ailine Stolz, Norman Ertych, and Holger Bastians

Review

406  Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
  Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, and Ron H.J. Mathijsen

HUMAN CANCER BIOLOGY

416  Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis
  Moriko Ito, Louise Barys, Terence O’Reilly, Sophie Young, Bella Gorbacheva, John Monahan, Sabine Zumstein-Mecker, Peter F. Choong, Ian Dickinson, Philip Crowe, Christine Hemmings, Jayesh Desai, David M. Thomas, and Joanna Lisztwan

427  Expression and Functional Significance of HtrA1 Loss in Endometrial Cancer
  Sally A. Mullany, Mehdi Moslemi-Kebria, Ramandeep Rattan, Ashwani Khurana, Amy Clayton, Takayo Ota, Andrea Mariani, Karl C. Podratz, Jeremy Chien, and Vijji Shridhar

437  Endogenous Versus Tumor-Specific Host Response to Breast Carcinoma: A Study of Stromal Response in Synchronous Breast Primaries and Biopsy Site Changes
  Julie M. Wu, Andrew H. Beck, Lisa L. Pate, Daniela Witten, Shirley X. Zhu, Kelli D. Montgomery, Kimberly H. Allison, Matt van de Rijn, and Robert B. West

CANCER THERAPY: PRECLINICAL

447  Vandetanib Improves Anti-Tumor Effects of L19mTNF in Xenograft Models of Esophageal Cancer
  Marika Crescenzzi, Luca Persano, Giovanni Esposito, Elisabetta Zulato, Laura Borsì, Enrica Balza, Alberto Ruol, Ermanno Ancona, Stefano Indraccolo, and Alberto Amadori

459  Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis
  Hilary A. Kenny, Payton Leonhardt, Andras Ladayi, S. Diane Yamada, Anthony Montag, Hae Kyung Im, Sujatha Jagadeeswaran, David E. Shaw, Andrew P. Mazar, and Ernst Lengyel
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>472</td>
<td>HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation</td>
<td>David Liska, Chin-Tung Chen, Thomas Bachleitner-Hofmann, James G. Christensen, and Martin R. Weiser</td>
</tr>
<tr>
<td>483</td>
<td>Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth</td>
<td>Nagathihalli S. Nagaraj, M. Kay Washington, and Nipun B. Merchant See commentary p. 393</td>
</tr>
<tr>
<td>494</td>
<td>Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma</td>
<td>Kathleen I. Pishas, Fares Al-Ejeh, Irene Zinonos, Raman Kumar, Andreas Evdokiou, Michael P. Brown, David F. Callen, and Paul M. Nielsen</td>
</tr>
<tr>
<td>505</td>
<td>Notch Pathway Inhibition Significantly Reduces Rhabdomyosarcoma Invasiveness and Mobility In Vitro</td>
<td>Josep Roma, Anna Masià, Jaume Reventós, Josep Sánchez de Toledo, and Soledad Gallego</td>
</tr>
<tr>
<td>514</td>
<td>Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer</td>
<td>Banibrata Sen, Shaohua Peng, Babita Saigal, Michelle D. Williams, and Faye M. Johnson</td>
</tr>
<tr>
<td>525</td>
<td>Forkhead Transcription Factor FOXO1 is a Direct Target of Progestin to Inhibit Endometrial Epithelial Cell Growth</td>
<td>Satoru Kyo, Junko Sakaguchi, Tohru Kiyono, Yutaka Shimizu, Yoshiko Maidai, Yasunari Mizumoto, Noriko Mori, Mitsuhiro Nakamura, Masahiro Takakura, Kiyohiko Miyake, Masaru Sakamoto, and Masaki Inoue</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>581</td>
<td>A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer</td>
<td>Martijn P. Lolkema, Hendrik-Tobias Arkenau, Kevin Harrington, Patricia Roxburgh, Rosemary Morrison, Victoria Roulstone, Katie Twigger, Matt Coffey, Karl Mettinger, George Gill, T.R. Jeffry Evans, and Johann S. de Bono</td>
</tr>
<tr>
<td>589</td>
<td>Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children’s Oncology Group Report</td>
<td>Jack M. Su, Xiao-Nan Li, Patrick Thompson, Ching-Nan Ou, Ashish M. Ingle, Heidi Russell, Ching C. Lau, Peter C. Adamson, and Susan M. Blaney</td>
</tr>
</tbody>
</table>
Modulation of Genetic and Epigenetic Biomarkers of Colorectal Cancer in Humans by Black Raspberries: A Phase I Pilot Study
Li-Shu Wang, Mark Arnold, Yi-Wen Huang, Christine Sardo, Claire Seguin, Edward Martin, Tim H.-M. Huang, Ken Riedl, Steven Schwartz, Wendy Frankel, Dennis Pearl, Yiqing Xu, John Winston III, Guang-Yu Yang, and Gary Stoner

Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors
Rochelle Bagatell, Cynthia E. Herzog, Tanya M. Trippett, Joseph F. Grippo, Georgina Cirrincione-Dall, Elizabeth Fox, Margaret Macy, Jennifer Bish, Patricia Whitcomb, Alberta Aiken, Gerry Wright, Sergey Yurasov, Frank M. Balis, and Lia Gore

Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Astrid A.M. van der Veldt, Karel Eechoute, Hans Gelderblom, Jourik Gietema, Henk-Jan Guchelaar, Nielka P. van Erp, Alfons J.M. van den Eertwegh, John B. Haanen, Ron H.J. Mathijssen, and Judith A.M. Wessels

Correction: Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

Correction: In vitro and Clinical Studies of Gene Therapy with Recombinant Human Adenovirus-p53 Injection for Oral Leukoplakia

ABOUT THE COVER
Rapid restoration of tumor microvasculature and perfusion in esophageal cancer xenografts treated with a vascular disrupting agent. Kyse-30 tumors were analyzed two weeks after administration of one single dose of the immunoconjugate L19mTNFa. Microvessels were stained by anti-CD31 (red), whereas perfusion was evaluated by injection of Dextran-FITC 70 kDa (green). Nuclei were stained by TOPRO-3 (blue). For further details, please see Crescenzi and coworkers on page 447 in this issue.
Clinical Cancer Research

17 (3)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/17/3

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/17/3.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.